2018-10-16 - OBSERVABLE Face-to-face Meeting

• @Jim Campbell

• @Rob Hausam

• @stefan.schulz

• @Farzaneh Ashrafi

• @Jesse Efron

• @Former user (Deleted)

• @Former user (Deleted)

• @Scott Campbell

• @Former user (Deleted)

• @Former user (Deleted)

• @Daniel Karlsson

• @Former user (Deleted)

• @Patricia Houghton

• @Former user (Deleted)

• @Former user (Deleted)

• @Jostein Ven

• @Former user (Deleted)

• @Keng-Ling Wallin

• @Former user (Deleted)

• @Anna Rossander

• @Feikje Hielkema

1

Welcome & apologies

@Daniel Karlsson

• Remember recording!

2

Conflicts of interest

@Daniel Karlsson

• None stated

3

Previous minutes

@Daniel Karlsson

• Approved

4

Susceptibility test products

@Daniel Karlsson

Draft editorial guidelines: Editorial Guidelines for Diagnostic Products Used for Susceptibility Testing

It was decided to recommend representation the physical form of the susceptibility test product, and also to use the | has presentation strenght... | attributes (as opposed to other strength attributes).

5

Diastolic arterial pressure and how to go forward with existing Observables

Together with EAG

Immediately after coffee

See comments on this page.

The FSNs are generally under-specified compared to how concepts have been used. We need to decide whether to retire, rename, remodel, add or leave as is.

E.g. the blood pressure observables FSNs do not specify time aspect. Can we assume that they are single point in time or not?

The guidance given by the EAG was that we should allow more consideration of reasonable clinical interpretation and also to allow updating and clarification of FSNs if deemed necessary. Data concerning clinical use of the concepts should be used to inform decisions. Ambiguous concepts which are not in significant use may be retired.

As this might disrupt implementations the updated guidance should be discussed with the MF and CMAG.

6

Observables MRCM

@Daniel Karlsson

We have previously had some discussions of extending the concept model to encompass additional attributes and allowed values.

These include:

• | Direct substance | - analog to | Direct site |, e.g. a protein substance could be a proxy for genetic configuration, with the range of << 105590001 | Substance |.

• Extend | Technique | allowed values to include << | Assessment scales | - was discussed previously (long time ago) to allow representation of Assessment scale observables. Scales typically includes an instrument used to collect information.

Presentation here

It was decided to recommend making the above changes to the MRCM.

7

Primary tumor site

@Jim Campbell

8

Target observables

Copied from the Vital signs incept./elaborat. document:

Target observables

Among the 46680005 | Vital sign (observable entity) | observables, there are a few "target" observables: 428420003 | Target heart rate (observable entity) |, 315612005 | Target systolic blood pressure (observable entity) |, and 315613000 | Target diastolic blood pressure (observable entity) |. These concepts would not be considered vital signs according to the definition used in this document. While the representation of such targets have not yet been elaborated on, it is clear that a target observable is distinct from a "ordinary" observable, particularly true for e.g. 390734006 | Target weight (observable entity) | and 27113001 | Body weight (observable entity) |. There are related JIRA tickets: IHTSDO-457, PCP-5, IHTSDO-39 and also some potentially related tickets: IHTSDO-356, IHTSDO-308.

Here is a presentation from a previous Observables meeting.

Here is an updated presentation.

9

Observables for clinical trials

@Former user (Deleted)

10

Next meeting

@Daniel Karlsson

• 2018-11-19 (or do we want to go back to twice per month?)

11

AOB

@Daniel Karlsson